|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||A recombinant protein containing aa 1-213 of human VHL|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||2-4 µg/ml|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 6 publications below|
MA5-13937 targets von Hippel-Lindau Protein in IHC (P), ICC/IF and WB applications and shows reactivity with Human and mouse samples.
The MA5-13937 immunogen is a recombinant protein containing aa 1-213 of human VHL.
Molecular genetic studies suggest that VHL is a tumor-suppressor gene. Alterations in the von Hippel-Lindau (VHL) gene are correlated with a diverse group of neoplasms including hemangioblastoma, clear cell renal carcinoma (RCC), and pheochromocytoma. Two transcriptional elongation factors, Elongin B and C, are shown to bind in vitro and in vivo to a short, colinear region of the VHL protein (pVHL) that is frequently mutated in human tumors. It is proposed that pVHL functions in vivo as a negative regulator of transcription elongation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
KAI1 suppresses HIF-1¿ and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer.
MA5-13937 was used in immunohistochemistry to study the mechanism by which the KAI1 metastasis-suppressor gene reduces expression of HIF-1alpha and VEGF in prostate cancer
|Park JJ,Jin YB,Lee YJ,Lee JS,Lee YS,Ko YG,Lee M||BMC cancer (12:null)||2012|
The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt.
MA5-13937 was used in immunohistochemistry to investigate the expression of tumor suppressor genes in renal cell carcinoma in Upper Egypt
|Nagi FM,Omar AA,Mostafa MG,Mohammed EA,Abd-Elwahed Hussein MR||Ultrastructural pathology (35:79)||2011|
Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
MA5-13937 was used in immunohistochemistry to examine the prognostic significance of cell necrosis for nonmetastatic clear cell renal cell carcinoma
|Minervini A,Di Cristofano C,Gacci M,Serni S,Menicagli M,Lanciotti M,Salinitri G,Rocca CD,Lapini A,Nesi G,Bevilacqua G,Minervini R,Carini M||The Journal of urology (180:1284)||2008|
Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.
MA5-13937 was used in immunohistochemistry to investigate the prognostic value of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma
|Di Cristofano C,Minervini A,Menicagli M,Salinitri G,Bertacca G,Pefanis G,Masieri L,Lessi F,Collecchi P,Minervini R,Carini M,Bevilacqua G,Cavazzana A||The American journal of surgical pathology (31:1875)||2007|
Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
MA5-13937 was used in immunohistochemistry to investigate the expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma
|Lee S,Garner EI,Welch WR,Berkowitz RS,Mok SC||Gynecologic oncology (106:311)||2007|
Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance.
MA5-13937 was used in immunohistochemistry to investigate the differentially expressed genes in salivary gland neoplasms
|Maruya S,Kim HW,Weber RS,Lee JJ,Kies M,Luna MA,Batsakis JG,El-Naggar AK||The Journal of molecular diagnostics : JMD (6:180)||2004|